- ►diabetesjournals.org J Mu, J Woods, YP Zhou, RS Roy, Z Li, E Zycband, Y … - Diabetes, 2006 - Am Diabetes Assoc Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of incretin
hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major unanswered question
concerns the potential ability of DPP-4 inhibition to have beneficial disease-modifying ... Cited by 127 - Related articles - BL Direct - All 9 versions
- ►januvia.se [PDF] I Raz, M Hanefeld, L Xu, C Caria, D Williams-Herman, … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis The aim of this study was to assess the efficacy and safety of sitagliptin
(MK-0431) as mono- therapy in patients with type 2 diabetes mellitus and inadequate glycaemic
control (HbA 1c Q7% and e10%) on exercise and diet. Methods A total of 521 patients ... Cited by 167 - Related articles - All 5 versions
- ►diabetesjournals.org JA Pospisilik, J Martin, T Doty, JA Ehses, N Pamir, FC … - Diabetes, 2003 - Am Diabetes Assoc Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth,
differentiation, and cell survival to well-documented, potent insulinotropic effects. ... Cited by 163 - Related articles - BL Direct - All 4 versions
GA Herman, C Stevens, K Van Dyck, A Bergman, … - Clinical Pharmacology & …, 2005 - nature.com Background: Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[1,2,4]triazolo[
4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine]) is an orally active, potent, and
selective inhibitor of dipeptidyl peptidase IV (DPP-IV) currently in phase III development ... Cited by 115 - Related articles - All 6 versions
R Scott, M Wu, M Sanchez, P Stein - International journal of …, 2007 - interscience.wiley.com The aim of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4
inhibitor, sitagliptin, in patients with type 2 diabetes who have inadequate glycaemic control on
diet and exercise. In a randomised, double-blind, placebo- and active-controlled study, ... Cited by 100 - Related articles - BL Direct - All 5 versions
AJ Bergman, C Stevens, YY Zhou, B Yi, M Laethem, M … - Clinical therapeutics, 2006 - Elsevier This double-blind, randomized, placebo-controlled,incremental oral-dose study was conducted
at SGS Biopharma, Antwerp, Belgium. Healthy, nonsmoking male volunteers aged 18 to 45 years
with a creatinine clearance rate of >80 mL/min and normoglycemia and weighing within ... Cited by 94 - Related articles - All 4 versions
GR Lankas, B Leiting, RS Roy, GJ Eiermann, MG … - Diabetes(New York, NY …, 2005 - cat.inist.fr Dipeptidyl peptidase(DPP)-IV inhibitors are a new approach to the treatment of type 2
diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline
dipeptidase(QPP), DPP 8, and DPP 9; DPP-IV is a key regulator of incretin hormones, but ... Cited by 144 - Related articles - BL Direct - All 2 versions
D Kim, L Wang, M Beconi, GJ Eiermann, MH … - Journal of medicinal …, 2005 - ncbi.nlm.nih.gov A novel series of beta-amino amides incorporating fused heterocycles, ie,
triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV
(DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ ... Cited by 189 - Related articles - All 5 versions
P Aschner, MS Kipnes, JK Lunceford, M Sanchez, … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Sitagliptin 100 and 200 mg produced significant (P < 0.001) placebo-subtracted
reductions in A1C (−0.79 and −0.94%, respectively) and fasting plasma glucose (−1.0
mmol/l [−17.1 mg/dl] and −1.2 mmol/l [−21.3 mg/dl], respectively). Patients with baseline ... Cited by 195 - Related articles - BL Direct - All 13 versions
D Holmes - Horm Metab Res, 2006 - rima.org The incretin hormones ± glucose−dependent insulinotropic poly− peptide (GIP) and particularly
glucagon−like peptide−1 (GLP−1) ± have been reported to exert multiple metabolic effects that
con− tribute to the regulation of glucose levels in vivo [1±3]. Strate− gies to enhance the ... Cited by 120 - Related articles - View as HTML - BL Direct - All 4 versions
